The finding carries real technical weight because it reframes a long-standing clinical question. Sickle cell anemia results from a single point mutation in the beta-globin gene that causes hemoglobin S polymerization under low oxygen conditions, leading to the characteristic sickling of red blood cells, vaso-occlusive crises, chronic hemolysis, and progressive organ damage. For decades, clinicians have debated whether children with sickle cell anemia face heightened susceptibility to intestinal parasites, either because of altered gut immunity, repeated transfusions, nutritional deficits, or the general frailty that accompanies chronic hemolytic disease. The Kosti data suggest the answer is no, at least not in a way that shows up as a measurable difference in infection prevalence. Instead, the parasites appear to be an extrinsic problem, driven by contaminated water, poor sanitation, and living conditions that expose all children in the region regardless of their hemoglobin genotype.

The parasite landscape itself tells a detailed story. Among children with sickle cell anemia, Giardia intestinalis dominated at 62 percent, followed by Entamoeba histolytica or Entamoeba dispar at 54 percent, Entamoeba coli at 31 percent, and Hymenolepis nana at 1 percent. Among non-sickle cell children, the picture shifted: Entamoeba coli was the most common parasite at 69 percent, with the other species present at lower rates. Giardia intestinalis, a flagellated protozoan that colonizes the small intestine and disrupts nutrient absorption through its adherence to the intestinal wall, emerged as the dominant pathogen in the sickle cell group. This is significant because Giardia infection can compound the nutritional challenges that children with sickle cell anemia already face, given their elevated metabolic demands and the growth delays that often accompany chronic hemolysis.

The distinction between Entamoeba histolytica and Entamoeba dispar deserves particular attention. These two species are morphologically identical under light microscopy, which is why the study reports them together as a single category. Entamoeba histolytica is the pathogenic species responsible for amoebic dysentery and invasive disease, capable of destroying host tissue through its cytotoxic activity, while Entamoeba dispar is generally regarded as non-pathogenic. Without molecular differentiation techniques such as polymerase chain reaction, the true proportion of pathogenic infections within that 54 percent category remains uncertain. This is a recognized limitation of microscopy-based parasitology in resource-limited settings, where the formal ether concentration technique and direct wet mount remain the standard diagnostic tools.

The diagnostic methodology itself is worth unpacking. Each of the 200 stool samples was examined using two complementary techniques: direct wet preparation, which allows rapid visualization of motile trophozoites in fresh samples, and the formal ether concentration technique, which concentrates cysts, ova, and larvae from larger stool volumes to increase sensitivity. The concentration step is critical because many intestinal parasites shed intermittently, and direct examination alone can miss low-burden infections. By combining both approaches, the investigators maximized their detection capacity, though even this dual method cannot distinguish morphologically identical species or detect parasites present below the threshold of microscopic visibility.

Age emerged as a meaningful risk factor in the analysis. Infection prevalence was higher among children older than five years, a pattern consistent with the epidemiology of intestinal parasites in endemic regions. Older children spend more time playing outdoors, have wider contact with contaminated soil and water, and are less likely to be exclusively breastfed or protected within household environments that shield infants from environmental exposure. This age gradient also aligns with the natural history of Giardia and Entamoeba transmission, which depends on ingestion of contaminated food or water and fecal-oral spread within households and communities.

The clinical implications for sickle cell care are substantial. Children with sickle cell anemia already contend with a cascade of complications: recurrent vaso-occlusive pain crises, acute chest syndrome, stroke risk, splenic dysfunction that impairs immune defense against encapsulated bacteria, and chronic anemia that requires careful transfusion management. Adding a heavy parasitic burden to this picture creates a dangerous synergy. Giardia infection impairs fat and carbohydrate absorption and can cause malabsorption syndromes that worsen growth failure. Entamoeba histolytica, when genuinely pathogenic, causes bloody diarrhea and can invade the intestinal wall, potentially triggering systemic inflammation in children whose bodies are already stressed by chronic hemolysis. Even non-pathogenic parasites like Entamoeba coli serve as markers of fecal contamination, signaling that a child is being repeatedly exposed to enteric pathogens, some of which may be bacterial or viral and harder to detect.

What makes the study particularly valuable is its case-control design within a single emergency department setting. By recruiting both sickle cell and non-sickle cell children from the same pediatric emergency population, the investigators controlled for many confounders that typically plague parasitology studies in endemic areas. Both groups came from the same geographic catchment, faced similar water and sanitation conditions, and were examined with identical diagnostic protocols. The near-identical prevalence rates, 86 percent versus 82 percent, therefore represent a clean comparison rather than an artifact of different sampling frames. The absence of a statistically significant association between sickle cell status and parasitic infection is a finding that should redirect clinical attention from genetic predisposition toward environmental intervention.

The public health message that follows is direct. If intestinal parasitic infections are driven by extrinsic factors rather than by sickle cell biology, then the solution lies in water treatment, sanitation infrastructure, hygiene education, and routine deworming and antiparasitic programs that target all children in the community, not just those with hemoglobin disorders. Sudan, like many tropical countries, faces persistent challenges with intestinal parasites, and the extraordinarily high prevalence documented in Kosti, exceeding 80 percent in both groups, reflects a level of environmental contamination that demands systemic response. For the sickle cell community specifically, the study suggests that pediatric sickle cell clinics in endemic regions should incorporate routine stool screening and antiparasitic treatment into standard care, not because sickle cell patients are uniquely vulnerable, but because they are being exposed at the same rate as everyone else while carrying a chronic condition that makes any additional insult more dangerous.

The research team, led by Abdelhakam G. Tamomh of the University of El Imam El Mahdi in Kosti, working with colleagues in Sudan and Ghana, conducted the study with institutional ethics approval and informed consent from all participants or their parents, adhering to the Declaration of Helsinki. The work received no external funding, and the authors declare no competing interests. Published as an open access article under a Creative Commons license, the study adds to a growing body of evidence that the health burdens of children with sickle cell anemia in resource-limited settings cannot be addressed through hematology alone. The parasites in their guts are a community problem, and solving it requires looking beyond the blood smear to the water supply, the toilet, and the playground.

Subject of Research: Parasitology and Pediatric Hematology

Article Title: Intestinal parasitic infections and associated risk factors in Sudanese pediatric sickle cell patients

Article References: Tamomh, A. G., Walana, W., Ibrahim, R. M., Elamin, E., Ali, M. O., Ali, H. O., & Aldaw, T. H. (2026). Intestinal parasitic infections and associated risk factors in Sudanese pediatric sickle cell patients. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07647-z

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07647-z

Keywords: intestinal parasitic infections, sickle cell anemia, Sudan, pediatric health, Giardia intestinalis, Entamoeba histolytica, public health, BMC Pediatrics, Intestinal, parasitic, infections, associated

The study team, led by Rosalon Guvengue Caputo Pedro of Clínica Sagrada Esperança and the Universidade da Beira Interior in Portugal, examined electronic medical records from all children aged one month to fifteen years admitted to the hospital’s Department of Pediatrics between January and December 2024. Of 1,169 pediatric admissions during that twelve-month window, 262 involved chronic diseases and met the eligibility criteria. Within that group, 97 children — 37.0 percent — carried a diagnosis of sickle cell anemia, making it the most common chronic condition on the ward and a dominant driver of pediatric inpatient care at the facility.

Sickle cell anemia is the most severe common form of sickle cell disease, a group of inherited disorders caused by a single mutation in the gene encoding hemoglobin, the oxygen-carrying protein inside red blood cells. The mutation causes hemoglobin molecules to polymerize into stiff rods when oxygen levels drop, deforming the normally pliable disc-shaped red cells into rigid crescents. These sickled cells clog small blood vessels, break down prematurely, and deprive tissues of oxygen, producing the disease’s hallmark complications: episodic vaso-occlusive pain crises, chronic hemolytic anemia, stroke, acute chest syndrome, and heightened vulnerability to serious infections. Sub-Saharan Africa carries the heaviest global burden of the disease, and Angola sits squarely within the high-prevalence belt that stretches across the continent.

What makes the new findings striking is how sharply the clinical profiles of the two patient groups diverged. Children with sickle cell anemia had a median of two previous hospitalizations before the admission captured in the study, with an interquartile range stretching from zero to five, while children with other chronic diseases had a median of zero, with an interquartile range of zero to one. That difference, highly statistically significant, underscores a pattern familiar to hematologists: sickle cell anemia is not a single catastrophic event but a relapsing condition that repeatedly pulls children back into hospital beds throughout childhood.

The intensity of each admission also differed. Children with sickle cell anemia spent a median of seven days in the pediatric intensive care unit, compared with three days for children with other chronic conditions, and their overall hospital stays ran longer, with a median of five days versus four. Both differences reached statistical significance. In practical terms, a single child with sickle cell anemia could occupy scarce pediatric intensive care capacity for twice as long as a peer admitted with another chronic illness, a sobering calculation for any health system weighing how to allocate limited beds, ventilators, and nursing staff.

Laboratory data told a parallel story of physiological stress. On admission, children with sickle cell anemia had markedly lower hemoglobin levels than their counterparts with other chronic diseases, reflecting the chronic hemolysis that defines the disorder. Their white blood cell counts and C-reactive protein levels were also higher, consistent with the inflammatory flare-ups and infections that frequently precipitate sickle cell admissions. When the researchers used median regression to adjust for age and sex, the hemoglobin gap persisted: children with sickle cell anemia had an adjusted median hemoglobin concentration 4.47 grams per deciliter lower than the comparison group, a difference so large it approaches the threshold at which transfusion becomes medically urgent.

Treatment patterns mirrored the underlying severity. Seventy-six percent of children with sickle cell anemia received analgesia during their admission, compared with 45 percent of children with other chronic diseases, reflecting the prominence of vaso-occlusive pain as a reason for hospitalization. More dramatically, 26 percent of the sickle cell group required blood transfusion, five times the rate seen in the other chronic disease group. Every one of these differences was statistically significant. For a country where safe blood supplies depend on voluntary donation and cold-chain logistics, a transfusion demand concentrated in a single disease category represents both a clinical challenge and a public health planning problem.

Notably, in-hospital mortality was low in both groups and did not differ significantly between them. The authors are careful to place an important caveat on that encouraging figure. The study was conducted in a well-resourced private tertiary hospital serving a predominantly insured population in Luanda, and the outcomes observed there cannot be assumed to represent the experience of most Angolan children. Across the wider region, where diagnosis may come late, follow-up may be fragmented, and disease-modifying therapy such as hydroxyurea may be inaccessible, mortality from sickle cell disease remains far higher. The low death rate in this cohort is best read as a portrait of what good tertiary care can achieve, not as a measure of the national situation.

The retrospective design carries its own limitations. Because the analysis relied on routinely collected electronic medical records, it captured only children who reached and were admitted to this particular hospital, potentially missing the sickest children who never arrived and the milder cases managed as outpatients. The single-center, single-year window limits generalizability, and the comparison group of children with other chronic diseases was heterogeneous, spanning a range of conditions with different natural histories. Still, the study’s strength lies in its direct head-to-head comparison of resource utilization, an angle rarely quantified in African pediatric settings where data on chronic childhood illness remain scarce.

The authors argue that their findings should sharpen priorities for Angolan child health policy. Strengthening early diagnosis — most powerfully through newborn screening programs that identify affected infants before their first crisis — building structured follow-up, expanding access to disease-modifying therapy such as hydroxyurea, and ensuring equitable access to comprehensive pediatric sickle cell care should remain national priorities. Globally, the study adds to a growing body of evidence that sickle cell disease, long overshadowed by infectious diseases in global health funding and research agendas, is a chronic condition whose burden on hospitals, families, and health budgets in Africa is enormous and measurable. As survival improves with better care, more children with sickle cell anemia will live into adolescence and adulthood, making the investment case for systematic, lifelong disease management stronger with every study that documents its weight on the wards.

Subject of Research: Hospital burden of sickle cell anemia among children in Angola

Article Title: Burden of sickle cell anemia among hospitalized children in Angola: a retrospective study

Article References: Pedro, R. G. C., Caputo, E. O., Valente, G. B., Cassule, L. A., & Jorge, A. M. M. (2026). Burden of sickle cell anemia among hospitalized children in Angola: a retrospective study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07666-w

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07666-w

Keywords: sickle cell anemia, pediatrics, Angola, hospitalization, chronic disease, anemia, blood transfusion, healthcare utilization, morbidity, sub-Saharan Africa, retrospective study, pediatric intensive care

Hydroxyurea has long been the cornerstone disease-modifying therapy for sickle cell anemia, the homozygous HbSS or HbSβ0-thalassemia genotypes that produce the most severe disease course. The drug works partly by reactivating fetal hemoglobin production, reducing the polymerization of sickle hemoglobin that drives red cell sickling, painful crises, and organ damage. Yet despite decades of clinical use, the precise relationship between dose and both clinical benefit and hematologic harm has remained uncertain, particularly across the diverse populations in which the disease is now treated.

To resolve this, the researchers conducted a systematic review and one-stage multilevel dose-response meta-analysis encompassing randomized trials, nonrandomized comparative studies, and longitudinal cohorts of children and adults with sickle cell disease. The quantitative synthesis focused principally on sickle cell anemia, with hydroxyurea dose expressed in mg/kg/day and achieved or maintenance doses preferred over starting doses. The primary benefit outcome was the rate of recurrent vaso-occlusive crises, while the primary safety outcomes were annual risks of severe or treatment-limiting neutropenia and thrombocytopenia, the two cytopenias that most often force dose reductions or discontinuation.

The modeling strategy was unusually rigorous. The team fitted Emax maximum-effect dose-response models as their primary analysis, testing linear and dose-independent alternatives in sensitivity analyses, and prespecified a decision rule requiring predicted annual neutropenia risk of no more than 5 percent and thrombocytopenia risk of no more than 3 percent, with at least an 80 percent simulation-derived probability that both criteria would be met simultaneously. Any eligible dose also had to retain near-optimal crisis control.

The results revealed a striking asymmetry between benefit and risk across the dose range. Empirical support for the primary analysis clustered between 20 and 28 mg/kg/day, and within that window recurrent vaso-occlusive crisis rates continued to fall, from a predicted 39.8 events per 100 person-years at 20 mg/kg/day to 32.5 at 28 mg/kg/day. Critically, the data showed no efficacy plateau: the Emax ED50 hit the upper limit of the prespecified search grid, and a simpler linear model actually fit marginally better, suggesting that whatever additional crisis reduction higher doses confer had not yet been exhausted within the observed range.

Safety told a different story. Predicted annual risk of severe or treatment-limiting neutropenia climbed steeply and early, from 1.98 percent at 20 mg/kg/day to 3.74 percent at just 21.5 mg/kg/day and 5.63 percent at 22.5 mg/kg/day. Thrombocytopenia, by contrast, remained uncommon and showed little dose dependence. Under the prespecified joint safety rule, the probability that both criteria were met was 87.1 percent at 20 mg/kg/day, 85.6 percent at 21 mg/kg/day, but only 77.8 percent at 21.5 mg/kg/day, failing the 80 percent threshold. The authors cautioned that because safety evidence was sparse and the joint classification depended partly on the relation between the two safety models, the low-20-mg/kg/day range should be read as an approximate safety transition rather than a precise toxicity threshold.

Within the empirically supported range, the lowest modeled recurrent crisis rate occurred at 28 mg/kg/day, and the unconstrained composite-benefit maximum at 25.5 mg/kg/day, but neither could clear the safety bar. Twenty-one mg/kg/day emerged as the highest dose satisfying the analytical rule, and the rounder conventional increment of 20 mg/kg/day was selected as the population reference dose, chosen from standard 2.5-mg/kg/day increments for practical prescribing.

The certainty of evidence behind these estimates was graded as very low for all three outcomes—recurrent crises, neutropenia, and thrombocytopenia—underscoring how much uncertainty remains. The review was prospectively registered with PROSPERO, and the authors emphasize that their decision framework, rather than any single trial, is what allows conflicting and sparse evidence to be converted into an actionable population-level recommendation.

Perhaps the most important clinical message is what the reference dose is not. The authors explicitly state that 20 mg/kg/day is neither a maximum tolerated dose nor a ceiling for treatment. Because crisis rates kept declining above 20 mg/kg/day, higher doses may well be appropriate for individual patients who need further clinical benefit, provided hematologic tolerance, adherence, and laboratory monitoring permit careful escalation. In resource-limited settings where laboratory surveillance is constrained, however, the population-level framework offers a defensible default that maximizes expected benefit while keeping predicted severe cytopenia risks within prespecified limits.

For the millions of people living with sickle cell anemia worldwide, most of them in sub-Saharan Africa, the findings translate decades of fragmented trial evidence into a single, transparent, quantitatively justified starting point for therapy—and a clear signal that the field still needs better safety data to push the benefit curve further.

Subject of Research: Dose-response relationship of hydroxyurea therapy in sickle cell anemia

Article Title: Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment

Article References: Paasi, G., Malaika, N., Ongodia, P., Amorut, D., & Olupot-Olupot, P. (2026). Hydroxyurea dosing in sickle cell anemia: a systematic review, dose-response meta-analysis, and population-level benefit-risk assessment. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07679-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07679-5

Keywords: hydroxyurea, sickle cell anemia, dose-response meta-analysis, vaso-occlusive crisis, neutropenia, thrombocytopenia, benefit-risk assessment, systematic review, fetal hemoglobin, pediatric hematology, BMC Pediatrics, drug dosing